Business
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results. Saint-Herblain (France), September 3rd, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. The s
About this update from Valneva Se
[{"type":"image","alt":"VALNEVA","displaySize":"","headline":null,"caption":"VALNEVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9l2h5dKc1PlSY26lXUAWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong immune response after third yearly booster dose in children and adults","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":77,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Significant anamnestic antibody response across all six serotypes","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results.","length":134,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":199,"olType":false},{"type":"text","content":"Saint-Herblain (France), September 3rd, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. The strong anamnestic immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving previous annual booster doses1,2 further demonstrating compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season.","length":526,"tagName":"p"},{"type":"text","content":"There are currently no approved human vaccines for Lyme disease, and VLA15 has advanced the furthest in clinical development, with two Phase 3 trials nearing completion. The Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 people in the U.S. are diagnosed and treated for Lyme disease each year, and 132,000 cases are reported annually in Europe.3,4 Vaccination has been completed in the pivotal Phase 3 study of VLA155, and subject to positive data, Pfizer aims to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorization Application ...